Skip to main content
. 2016 Nov 3;4(4):310–319. doi: 10.14218/JCTH.2016.00027

Table 1a. Comparison of treatment guidelines for treatment-naïve patients infected with HCV genotype 1.

Genotype AASLD/IDSA EASL WHO# APASL
1a

  • Sofosbuvir/ledipasvir (I-A)

  • Elbasvir/grazoprevir (I-A)

  • Sofosbuvir/velpatasvir (I-A)

  • PrOD/RBVa (I-A)

  • Sofosbuvir/simeprevir (I-A)

  • Sofosbuvir/daclatasvir (I-B)

Alternatives

  • Sofosbuvir/simeprevir ± RBVa* (II-B)

  • Elbasvir/grazoprevir ± RBVe (IIa-B)

  • Sofosbuvir/daclatasvir ± RBVa (IIa-B)

  • PegIFN-α/RBV/sofosbuvira (A1)

  • PegIFN-α/RBV/simeprevir, then PegIFN-α/RBV (24 weeks total) (B1)

  • Sofosbuvir/ledipasvirb (A1)

  • PrOD/RBVab (A1)

  • Sofosbuvir/simepravirb (B1)

  • Sofosbuvir/daclatasvirb (B1)

  • Sofosbuvir/daclatasvirab

  • Sofosbuvir/ledipasvirabcd

Alternatives

  • Simeprevir/sofosbuvirab*

  • PrOD/RBV a

  • Sofosbuvir/ledipasvir (A1)
1b

  • Elbasvir/grazoprevir (I-A)

  • Ledipasvir/sofosbuvir (I-A)

  • PrOD (I-A)

  • Sofosbuvir/simeprevir (I-A)

  • Sofosbuvir/velapatasvir (I-A)

  • Sofosbuvir/daclatasvir (I-B)

Alternatives

  • Sofosbuvir/daclatasvir ± RBVa

  • Sofosbuvir/simeprevir ± RBVa (IIa-B)

  • PegIFN-α/RBV/sofosbuvir (A1)

  • PegIFN-α/RBV/simeprevir, then PegIFN-α/RBV (24 weeks total) (B1)

  • Sofosbuvir/ledipasvirb (A1)

  • PrODb (A1)

  • Sofosbuvir/simepravir (A1)b (B1)

  • Sofosbuvir/daciatasvir (A1)b (B1)

  • Sofosbuvir/dalatasvirab

  • Sofosbuvir/ledipasvirabcd

Alternatives

  • Sofosbuvir/simepravir ab*

  • PrOD b

  • Sofosbuvir/ledipasvir (A1)

  • PrOD (A1)

  • Grazoprevir/elbasvir (A1)

  • Asunaprevir/daclatasvir (24 weeks)(A2)
*

Option in patients with a negative test result for the Q80K variant;

#

All regimens: strong recommendation, moderate quality of evidence.

a

24 weeks in patients with cirrhosis;

b

12 weeks with RBV in patients with cirrhosis;

c

Treatment may be shortened to 8 weeks in treatment-naïve persons without cirrhosis if baseline HCV RNA is below 6 million IU/mL;

d

If the platelet count is <75 × 103/μL, then 24 weeks of treatment with RBV should be given;

e

16 weeks if baseline NS5A RAVs for elbasvir.

Abbreviations: PrOD, Paritaprevir/ritonavir/ombitasvir/dasabuvir; RAVs, Resistance-associated variants; RBV, Ribavirin.

All treatment courses are 12 weeks unless indicated otherwise.